Filing Details
- Accession Number:
- 0001209191-13-039085
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-08-02 19:58:35
- Reporting Period:
- 2013-08-02
- Filing Date:
- 2013-08-02
- Accepted Time:
- 2013-08-02 19:58:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 858803 | Avanir Pharmaceuticals Inc. | AVNR | Pharmaceutical Preparations (2834) | 330314804 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1314596 | Keith Katkin | 20 Enterprise, Suite 200 Aliso Viejo CA 92656 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2013-08-02 | 15,500 | $4.84 | 479,607 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A portion of the proceeds from the sale will be used to pay required tax withholdings due upon the vesting of Restricted Stock Units granted to the Reporting Person. Following the sales reported on this Form 4, the Reporting Person has a total of 1,393,416 options to purchase shares of common stock that are vested and immediately exercisable and a total of 638,137 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 166,125 unvested Restricted Stock Units, of which 145,875 are performance-based Restricted Stock Units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.8205 to $4.8510, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
Billionaire Hedge Funds
